Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
NCT07402473
This study is recruiting at 7 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Predictive Signature (HARPS) to identify HARPS-positive breast cancers. To assess 3-year invasive disease-free survival (iDFS) in patients with HARPS-positive and HARPS-negative HER2-positive breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2-positive Early-stage Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rutgers, The State University of New Jersey
- Last updated on ClinicalTrials.gov
- April 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 7
- RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center · Elizabeth, NJ
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton · Hamilton, NJ
- RWJBarnabas Health - Monmouth Medical Center · Long Branch, NJ
- Rutgers Cancer Institute · New Brunswick, NJ
- RWJBarnabas Health - Newark Beth Israel Medical Center · Newark, NJ
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset · Somerville, NJ
- RWJBarnabas Health - Community Medical Center · Toms River, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.